Håkan Nelson

Develops treatment for cancer

MIAB's investment objective is to create value in their portfolio firms. Their investment strategy focuses on small to mid-sized technology-based firms primarily in the Öresund region of Sweden and Denmark. They look for developing firms in the expansion-phase. MIAB is an active investment partner. They typically take minority stakes. They seek to strengthen the portfolio firms' balance sheet, broaden their skills and widen their network to enable them to create value and sell at the appropriate time. They have invested in orally administered contrast medium for scanning of liver tumors by magnetic resonance imaging (MRI), therapeutic solutions for cancer treatment, development of molecularly imprinted polymers (MIPs), injectable filler for aesthetic surgery, allergy diagnostics and management, time-temperature system for monitoring the accumulated effect of temperature on products, and electroporation for research and laboratory use in vivo and in vitro.

Functions as a College/University

Øresund Healthcare is an active manager which provides equity financing for early and growth-stage capital requirements. The firm targets young companies operating in the healthcare sector, and industries such as medical devices, pharmaceuticals, and biotechnology. Øresund Healthcare invests in startups located in Denmark and Sweden, and looks to take minority stake positions in its investments, as well as a seat on the board.

Engages in acquisition, business development and long-term ownership of enterprises

Develops molecularly imprinted polymers

Provides HVAC, plumbing, refrigeration, and building installation and maintenance services

Provides employment training services

Acts as Private Equity Fund